P. Romero-aroca, Managing diabetic macular edema: The leading cause of diabetes blindness, World Journal of Diabetes, vol.2, issue.6, pp.98-104, 2011.
DOI : 10.4239/wjd.v2.i6.98

J. W. Yau, S. L. Rogers, and R. Kawasaki, Global Prevalence and Major Risk Factors of Diabetic Retinopathy, Diabetes Care, vol.35, issue.3, pp.556-564, 2012.
DOI : 10.2337/dc11-1909

C. Delcourt, P. Massin, and M. Rosilio, Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French population, Diabetes & Metabolism, vol.35, issue.6, pp.431-438, 2009.
DOI : 10.1016/j.diabet.2009.06.002

URL : https://hal.archives-ouvertes.fr/inserm-00394359

Q. D. Nguyen, D. M. Brown, and D. M. Marcus, Ranibizumab for Diabetic Macular Edema, Ophthalmology, vol.119, issue.4, pp.789-801, 2012.
DOI : 10.1016/j.ophtha.2011.12.039

J. F. Korobelnik, D. V. Do, and U. Schmidt-erfurth, Intravitreal Aflibercept for Diabetic Macular Edema, Ophthalmology, vol.121, issue.11, pp.2247-2254, 2014.
DOI : 10.1016/j.ophtha.2014.05.006

L. Hrarat, F. Fajnkuchen, and M. Boubaya, Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting, Ophthalmologica, vol.236, issue.4, pp.207-214, 2016.
DOI : 10.1159/000453006

D. S. Boyer, Y. H. Yoon, and R. Belfort-jr, Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema, Ophthalmology, vol.121, issue.10, pp.1904-1914, 2014.
DOI : 10.1016/j.ophtha.2014.04.024

E. Rahimy, A. Shahlaee, and M. A. Khan, Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema, American Journal of Ophthalmology, vol.164, pp.118-127, 2016.
DOI : 10.1016/j.ajo.2015.12.030

E. H. Wood, P. A. Karth, D. M. Moshfeghi, and T. Leng, Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab, Ophthalmic Surgery, Lasers and Imaging Retina, vol.46, issue.9, pp.950-954, 2015.
DOI : 10.3928/23258160-20151008-08

L. S. Lim, W. Y. Ng, and R. Mathur, Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab, Clinical Ophthalmology, vol.9, pp.1715-1718, 2015.
DOI : 10.2147/OPTH.S81523

N. Papadopoulos, J. Martin, and Q. Ruan, Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, vol.28, issue.281, pp.171-185, 2012.
DOI : 10.1200/JCO.2009.24.8252

P. U. Dugel, J. Hillenkamp, and S. Sivaprasad, Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials, Clinical Ophthalmology, vol.10, pp.1103-1110, 2016.
DOI : 10.2147/OPTH.S100764

L. Gutiérrez-benítez, E. Millan, L. Arias, P. Garcia, E. Cobos et al., Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy, Archivos de la Sociedad Espa??ola de Oftalmolog??a (English Edition), vol.90, issue.10, pp.475-480, 2015.
DOI : 10.1016/j.oftale.2015.10.019

I. Zhioua, O. Semoun, F. Lalloum, and E. H. Souied, INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA, Retina, vol.35, issue.7, pp.1429-1435, 2015.
DOI : 10.1097/IAE.0000000000000490

E. Pacella, A. R. Vestri, and R. Muscella, Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema, Clinical Ophthalmology, vol.7, pp.1423-1428, 2013.
DOI : 10.2147/OPTH.S48364

D. M. Brown, U. Schmidt-erfurth, and D. V. Do, Intravitreal Aflibercept for Diabetic Macular??Edema, Ophthalmology, vol.122, issue.10, pp.2044-2052, 2015.
DOI : 10.1016/j.ophtha.2015.06.017

H. Fassnacht-riederle, M. Becker, N. Graf, and S. Michels, Effect of aflibercept in insufficient responders to prior anti- VEGF therapy in neovascular AMD, " Graefe's Archive for, Clinical and Experimental Ophthalmology, vol.252, pp.1705-1709, 2014.

F. Forooghian, E. Y. Chew, C. B. Meyerle, C. Cukras, and W. T. Wong, Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis, Acta Ophthalmologica, vol.115, issue.2, pp.206-207, 2011.
DOI : 10.1016/j.ophtha.2008.07.007